Upharmacia - March 2016

Ukrainian Pharmaceutical Market Monthly
Upharmacia
Macroeconomic Environment | Market & Companies News |
Regulatory Updates | Healthcare News
Issue: 03 2016
UPharma Consulting is a consulting company, operating in the healthcare and pharma sectors. Our clients -
pharmaceutical companies, pharmacy chains, distributors, investment funds, banks, and other stakeholders in
the healthcare sector.
UPharma Consulting
Kiev / www.upharma-c.com / mailbox@upharma-c.com / +380 (44) 232-11-42

Ukrainian Pharmaceutical Market Monthly: March 2016
2015 2016
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb
MACROECONOMIC INDICATORS
Q1 Q2 Q3 Q4
GDP (US$ bn) 17.353 20.795 25.552 25.588
growth, % y-o-y -51% -35% -26% -17%
Export of Goods (US$ bn) 2.99 3.45 3.07 2.94 3.09 3.15 3.09 3.35 3.23 3.13 3.36 2.04 3.08
growth, % y-o-y -37% -32% -39% -41% -30% -34% -22% -22% -23% -21% -11% -31% 3%
Import of goods (US$ bn) 2.86 3.17 2.86 2.63 2.76 2.98 3.88 3.24 3.22 3.07 3.12 2.23 2.68
growth, % y-o-y -41% -35% -38% -46% -37% -34% -2% -30% - 27% -27% -32% -26% -6%
Industrial Production Sales (US$ bn) 4.56 5.51 5.91 5.65 5.79 5.71 5.42 5.72 6.29 5.92 6.37 4.93 4.93
growth, % y-o-y -54% -45% -33% -38% -35% -33% -23% -20% -21% -19% -17% -18% 8%
Retail Turnover of Enterprises (US$ bn) 1.44 1.61 1.66 1.94 1.83 1.94 1.88 1.86 2.04 1.80 2.01 1.60 1.50
growth, % y-o-y -61% -56% -40% -35% -38% -41% -32% -38% -31% -33% -29% -19% 4%
Unemployment Rate (%) 2.0 1.9 1.8 1.8 1.7 1.6 1.6 1.5 1.5 1.6 1.9 1.9 1.9
Average Salary (US$) 148 166 176 193 202 202 194 199 207 193 223 180 174
OFFICIAL CURRENCY EXCHANGE RATE
UAH / USD 24.5 23.3 22.7 20.9 21.2 21.8 21.6 21.8 21.8 23.3 23.4 24.3 26.4
UAH / EUR 27.8 25.3 24.5 23.3 23.8 23.9 24.0 24.5 24.6 25.1 25.4 26.3 29.3
PHARMACEUTI CAL INDUSTRY INDICATORS
Export of Pharma Products (mio USD) 12.05 13.37 13.46 13.00 15.36 13.85 9.01 13.79 12.2 11.7 15.77 8.31 13.33
growth, % y-o-y -42% -50% -44% -39% -39% -6% -54% -47% -37% -52% -28% -30% 11%
Import of Pharma Products (mio USD) 114.5 103.3 103.7 84.2 115.0 106.5 93.3 121.1 147.1 141.3 142.1 103.7 145.0
growth, % y-o-y -47% -67% -36% -60% -44% -47% -47% -31% -28% -24% -42% 15% 27%
Pharma Retail Sales, values (mio USD) 177.0 197.6 180.0 193.0 177.7 172.6 177.1 193.2 206.3 196.6 212.3 198.9 176.0
growth, % y-o-y -54% -47% -40% -28% -29% -32% -24% -28% -26% -20% -18% -17% -1%
Pharma Retail Sales, volumes (mio units) 143.9 141.5 122.6 124.5 118.4 119.5 122.5 126.7 130.2 129.0 136.4 133.6 126.8
growth, % y-o-y -15% -21% -20% -11% -9% -10% -8% -11% -5% -4% -5% 1% -12%
WACP (USD) 1.81 1.24 1.41 1.47 1.52 1.48 1.45 1.52 1.58 1.52 1.56 1.49 1.39
growth, % y-o-y -22% -40% -27% -23% -21% -23% -18% -19% -22% -18% -14% -23% -23%
CPI of Ukraine 134.5 145.8 160.9 158.4 157.5 155.3 152.8 151.9 146.4 138.1 134.6 131.9 126.9
Pharmaceutical Products CPI 155.5 170.3 164.7 159.5 153.5 151.8 149.4 145.8 142.1 146.6 143.3 140.3 132.7
Local Companies share, values (%) 38.5 39.6 40.7 41.5 41.7 41.8 41.4 41.4 41.4 41.7 40.9 42.3 42.9
Local Companies share, volumes (%) 75.2 77.1 77.6 77.6 77.9 78.4 78.2 76.5 75.7 75.8 76.7 75.6 76.5
MACROECONOMIC ENVIRONMENT
Description of the indicators:
MACROECONOMIC INDICATORS
GDP (Gross Domestic Product) is an aggregate measure of production equal to the sum of the
gross values added of all resident, institutional units engaged in production (plus any taxes, and
minus any subsidies, on products not included in the value of their outputs) calculated in current
prices. Converted from UAH to USD in accordance with an average official NBU exchange
rate in the corresponding period. Hereinafter: excluding the temporarily occupied territory of
the Autonomous Republic of Crimea and City of Sevastopol, as well as the part of zone of the
antiterrorist operation. Source: State Statistics Service of Ukraine.
Export of Goods is a sale of goods by Ukrainian subjects of foreign economic activities to foreign
subjects of foreign economic activities (including non-cash payment) with or without exportation
of these goods through the customs border of Ukraine, including the re-export of goods. Initially
calculated in USD. Source: State Statistics Service of Ukraine.
Import of Goods is a purchase (including non-cash payment) of goods by Ukrainian subjects
of foreign economic activities in foreign subjects of economic activities with or without the
importation of these goods into the territory of Ukraine, including the purchase of goods for
domestic consumption by establishments and organizations of Ukraine located abroad. Initially
calculated in USD. Source: State Statistics Service of Ukraine.
Industrial Production Sales is the value of industrial goods, which are actually shipped in the
period, as indicated in documents decorated as the basis for calculating with the buyer (customer),
regardless of income payments for them. Converted from UAH to USD in accordance with an
average official NBU exchange rate in the corresponding period. Source: State Statistics Service
of Ukraine.
Retail Turnover of Enterprises is the value of consumer goods sold via retail trade and
restaurants to the population by all operating enterprises. It also includes direct retail sales by
industrial, transport and other non-trade enterprises. In addition, retail turnover includes retail
sales of food products to departments, organizations and enterprises to provide meals to the
people they serve (at sanatoria, children’s care institutions, hospitals, etc.). Reflected in current
prices. Converted from UAH to USD in accordance with an average official NBU exchange rate in
the corresponding period. Source: State Statistics Service of Ukraine.
Unemployment Rate is a ratio (percent) of the unemployed registered at the State Employment
Service to the average annual population of working age. Source: State Statistics Service of
Ukraine.
Average Salary is an average value of remuneration in cash and in kind paid to employees for
time worked or work done. Converted from UAH to USD in accordance with an average official
NBU exchange rate in the corresponding period. Source: State Statistics Service of Ukraine.
Official Currency Exchange Rate is the rate established by the National Bank of Ukraine
under which Ukrainian national currency – UAH (Ukrainian hryvnia) will be exchanged for foreign
currency (USD or EUR). Calculated as average value in the corresponding period. Source: National
Bank of Ukraine.
PHARMACEUTICAL INDUSTRY INDICATORS
Export of Pharma Products is an export of goods related to the group “Pharmaceutical products”
under the Ukrainian Classification of Goods for Foreign Economic Activities. Initially calculated in
USD. Source: State Statistics Service of Ukraine.
Import of Pharma Products is an import of goods related to the group “Pharmaceutical products”
under the Ukrainian Classification of Goods for Foreign Economic Activities. Initially calculated in
USD. Source: State Statistics Service of Ukraine.
Pharma Retail Sales are retail sales of different product categories of “pharmacy basket” (drugs,
medical devices, cosmetics and food supplements) in values and volumes. Converted from UAH
to USD in accordance with an average official NBU exchange rate in the corresponding period.
Source: Morion.
WACP (Weighted average cost of a pack) is a ratio of pharma retail sales in values to pharma
retail sales in volumes.
CPI (Consumer price index) is an indicator of changes at the time of prices and tariffs for
commodities and services being purchased by the population for unproductive consumption
calculated to corresponding month of previous year. Source: State Statistics Service of Ukraine.
Pharma Products CPI is a Consumer price index of “Pharmaceutical products, medical products,
appliances and equipment” group calculated to corresponding month of previous year. Source:
State Statistics Service of Ukraine.
Local Companies Share is the share (percent) of sales related to Ukrainian companies in overall
pharma retail sales in values and volumes. Source: Morion
Table: Key Macroeconomic
Indicators in Ukraine
(Feb 2015-Feb 2016)

KEY ECONOMIC EVENTS
»» Ukraine’s real GDP fell 9.9% y-o-y in 2015, while nominal GDP reached UAH 1,979 bn or USD 89.2 bn by the
average exchange rate. However, the decline dynamics have been decreasing over the quarters of 2015 and in
4Q2015, real GDP decline was 1.4% y-o-y.
»» Economy Ministry of Ukraine reduced its GDP growth forecast from 1.0% to 0.0% y-o-y for 1H2016 due to trade
restrictions imposed by Russia and weak external demand. Later on, the Finance Minister said the government
projects 1% growth in 2016, not 2%, as expected earlier.
»» The National Bank of Ukraine intends to increase international reserves to USD 19.6 bn by the end of 2016, NBU
Head said. The NBU expects to reach funds by restoring relations with the international community. Currently,
the international reserves of Ukraine stand at USD 13.3 bn.
»» Ukraine has reached credit agreement with Japan for USD 200 mio to carry out economic reforms, Finance
Ministry reported.
»» Ukraine and Iran are to start implementing joint projects in agricultural sector and continue cooperation in
banking sector. Ukraine also proposed Iranian investors to participate in privatization of Ukrainian enterprises
and investing in forestry and fishing sector.
»» Fiscal revenues to the consolidated budget of Ukraine in Jan-Feb 2016 increased by 33.6% y-o-y to UAH 83.4
bn.
»» European Commission will recommend abolishing visas for Ukrainians in Apr, Jean-Claude Juncker said. In Mar,
the Ukrainian parliament has adopted the last law of “visa-free” package.
»» In Feb, industrial output in Ukraine increased by 7.6% y-o-y. The main drivers for growth were metals, mining
and machinery. Luhansk region recovered its industry by 2.5x y-o-y, while Donetsk region increased output by
26.9% y-o-y.
177.0
197.6
180.0
193.0
177.7
172.6
177.1
193.2
206.3
196.6 212.3 198.9
176.0
143.9
141.5
122.6
124.5
118.4
119.5
122.5
126.7
130.2 129.0
136.4
133.6
126.8
100
110
120
130
140
150
160
100
120
140
160
180
200
220
Pharma retail sales
2015 2016
Volumes (mio units)
Values (mio USD)
12.1
13.4 13.5 13.0
15.4
13.9
9.0
13.8
12.2
11.7
15.8
8.3
13.3
114.5
103.4 103.7
84.3
115.0
106.6
93.3
122.2
147.1
141.3
142.1
103.7
145.0
0
20
40
60
80
100
120
140
160
0
4
8
12
16
20
24
Ukraine's Internation trade
in pharma production
2015 2016
Export
Import
4.56
5.51
5.91
5.65
5.80 5.71
5.43
5.72
6.29
5.92
6.37
4.93 4.93
1.44
1.61 1.66
1.94
1.83
1.94
1.88 1.86
2.04
1.80
2.01
1.60
1.50
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0
1
2
3
4
5
6
7
Industrial production sales &
Retail turnover of enterprises surplus
2015 2016
Retail turnover of enterprises
Industrial producƟon sales
24.5 23.3 22.7
20.9 21.2 21.8 21.6 21.8 21.8
23.3 23.4 24.3
26.4
29.0
29.5
26.9
25.5 24.9
26.1 25.9 26.1
24.6 25.1 25.4
26.3
29.3
134.5
145.8
160.9 158.4 157.5 155.3 152.8 151.9
146.4 146.6
143.3
140.3
132.7
0
20
40
60
80
100
120
140
160
0
5
10
15
20
25
30
35
40
45
2015 2016
vs. Consumer Price Index
Official Currency Exchange Rates
Consumer Price Index
UAH / €
UAH / $

RECRUITING &
EXECUTIVE
SEARCH
We recruit pharma people in the
CIS region and focus on:
> Sales & Marketing
> Regulatory Affairs
> Quality Assurance
> Finances
> Operations
> Administration
We aim to be your trusted advisor
in People Management
Anastasiya MAXIMENKO
Partner, HR-Consulting
AMaximenko@upharma-c.com
+380 (44) 232-11-43
+380 (97) 953-68-14

MARKET & COMPANIES NEWS
Sanofi Ukraine
appointed new
Director
On Mar 1, Sanofi announced the
appointment of Guilhem Granier
as the Director of Sanofi Ukraine
and General Manager of the Rx
department. Mr. Granier has
replaced Jean-Paul Scheuer, who
has been heading the company
for seven years.
Guilhem Granier joined Sanofi
in 2000. In 2007, he had been
appointed as the company’s
Business Unit Director in Tunisia,
while in 2010 he became the
General Manager in Tunisia
and Libya. His last position was
Business Excellence Director of
Intercontinental region (Africa
States, Middle East, Eurasia and
South Asia).
“I have a quite diverse experience
of working in crisis conditions,
which I will try to use at my new
position in Ukraine,” Mr. Granier
said. “Certainly, my further work
will be based on what Jean-Paul
and Sanofi Ukraine’s team have
already built.”
Jean-Paul Scheuer will continue
working as County Chair of Sanofi
Gulf and Yemen region.
Liktravy reported
UAH 13.6 mio
profit in 2015
The biggest Ukrainian producer of
herbal preparations Liktravy has
finished 2015 with UAH 13.6 mio
net profit, the company’s officials
reported. The company’s profit
raised almost four times from
UAH 3.5 mio in 2014.
Liktravy produces more than
70 names of brands. Hallmarks
of the company are medicinal
herbs and phytotea. Liktravy’s
assets amounted UAH 180.2
mio, 99.35% of which are
owned by German company MB
Beteiligungs Gmbh.
GSK restricts
supply of
Infanrix™
vaccines to Ukraine
GSK Ukraine announced the
temporary restriction of supply
of Infanrix™ vaccines (Infanrix™
HEXA, Infanrix™ IPV, Infanrix™)
containing pertussis component
to Ukraine due to increased
global demand in ones and
limited production capacity.
The restrictions will apply to
requirements of the national
immunization program as well as
to supply to private clinics and
pharmacies. All other vaccines
of the company are supplied in
Ukraine as usual.
“The restrictions do not connect
with the issues of quality or
safety of our vaccines,” GSK’s
officials said. “We expect the
restrictions will apply only
shortly. But the terms could
change in respond to the external
environment.”
Later on, the company stated it
plans to register new vaccines
in Ukraine to eliminate the
deficit of vaccines containing
pertussis component. In case if
other companies are not able to
carry out the supply, GSK will
take steps to find an acceptable
solution, the company said.
Antibiotice will open
representative office
in Ukraine
Romanian pharmaceutical
company Antibiotice will open its
representative office in Vinnytsia
in 2016. The corresponding
agreement was reached between
the GM of the company and the
Head of Vinnytsia Region State
Administration.
Antibiotice was founded in
1995 and now develops and
produces generic drugs for
human use veterinary drugs and
the active ingredient Nystatin.
The company’s portfolio consists
of 148 products, which are
mainly intended for patients with
infectious diseases, but also for
cardiovascular, dermatological,
oncological, digestive and
central nervous system related
pathologies. Antibiotice is actively
expanding external markets; in
2014 the company exported
production for USD 25.6 mio.
InterChem is
developing
three new molecules
InterChem pharmaceutical
company has three molecules
under development, the Director
of the company Anatoliy Reder
said. Lately, InterChem has
finished another phase of clinical
trials of a product against a
sore throat. Nootropic drug for
memory restore is also in the
phase of clinical trials. InterChem
expects to register new medicines
following bioequivalence
procedure.
InterChem was the 25th
company on the Ukrainian
pharmaceutical market by sales
in 2015. The company’s primary
specialization is drugs for
nervous and respiratory systems.
The company plans to put its
new production facilities into
operation in Apr 2016. Currently,
InterChem considers the access
to the markets of East Africa,
particularly Kenya.
Indar received GMP
certificate in Brazil
National Health Surveillance
Agency of Brazil (ANVISA)
has granted Ukrainian insulin
producer Indar the International

GMP certificate. Indar has been
supplying recombinant insulins
in the form of ready-made
medicines in Brazil, where they are
prescribed to adults and children.
It was reported, that the company
had planned to put into operation
its insulin-manufacturing site in
Brazil in 2016.
Indar is the only insulin producer
in Ukraine, obtaining a full cycle
manufacturing of the preparation
– from substances to finished
dosage forms. Since 2012, 70.7%
of Indar’s shares are owned by the
State company “Ukrmedprom”.
Arterium
Corporation
launches a pregabalin drug
Ukraine’s 3rd
biggest
pharmaceutical company
Arterium Corporation has
launched Gabana™ (pregabalin)
for the treatment of neuropathic
pain. The drug is produced under
GMP standards at the facilities of
PJSC Kievmedpreparat (part of
Arterium Corporation). Gabana™
is a Rx drug, which claims to be
cost-effective for patients as
other pregabalin analogs are quite
expensive.
Arterium did not change its
positions on the Ukrainian
pharmaceutical market in 2015
despite the bankruptcy of the
company’s owner “Finance and
Credit” Group. The company’s
portfolio consists of more than
140 brands with an emphasis on
cardiovascular and antiinfective
groups.
Dr. Reddy’s
will launch new
drugs in Ukraine
Indian Dr. Reddy’s remains
optimistic regarding Ukrainian
pharmaceutical market
and continues its business
development in the country,
Executive VP of the company M.
V. Ramana said. The company
intends to strengthen its positions
in Ukraine by launching innovative
products. Thus, Dr. Reddy’s plans
to register molecules for the
treatment of cardiovascular and
neurological diseases as well as
new oncology drugs.
Dr. Reddy’s was 29th
company
in the Ukrainian pharmaceutical
market by sales in 2015.
AstraZeneca
Ukraine will
expand its oncological portfolio
AstraZeneca announced the
launch of Lynparza™ (olaparib)
for the treatment of ovarian
cancer onto Ukrainian market.
“Launching olaparib is a
major step towards achieving
leadership in the oncology field,”
the Director of AstraZeneca in
Ukraine Evgeniy Gaidukov said.
“The drug is at the forefront
in AstraZeneca’s oncological
portfolio and can significantly
improve the patients’ life.’
Olaparib is a poly (ADP-ribose)
polymerase inhibitor affecting
DNA repair processes. The drug
was endorsed for registration in
Ukraine in Nov 2015.
The government
endorsed Biofarma
to export blood
preparations
The Cabinet of Ministers of
Ukraine approved the MOH’s
proposition to provide PJSC
Biofarma, and Biofarma Plasma
LLC exclusive authority to sell
donor blood components and
made of blood preparations
outside Ukraine.
Biofarma is one of the biggest
pharmaceutical companies in
Ukraine producing more than
130 brands in 11 pharmaceutical
groups. The company’s key
activity is the manufacturing of
high-technological preparations
made of donor blood as well as
recombinant drugs and bacterial
preparations.
REGULATORY UPDATES
The Essential Documents in the
Sphere of the National Essential
Medicines List Have Been
Disclosed to the Public
The Order of MOH № 84 dated
11.02.2015, with which the
Regulation on the National List
of Essential Medicines and
the Regulation on the Expert
Committee on the Selection and
Use of Essential Medicines has
been approved.
The said provision establishes
that the drugs will be included
in the National List of Essential
Medicines (hereinafter - the
National List), taking into
account population incidence
rates, prevalence of disease
and mortality, evidence of the
comparative effectiveness
(performance), safety and cost-
effectiveness of medicines, as well
as industry standards in terms
of health and level of funding for
health care. The structure and
contents of national lists will be
based on the latest edition of the
Provided by

Basic List of Essential Medicines
recommended by WHO.
The next working step is to
create a competitive commission
for the formation of an Expert
Committee, which consists of
12-18 people, and the selection of
committee members on the basis
of equal access of candidates to
participate in the competition.
Once an expert committee under
the MOH is established, work
concerning the selection of drugs
to be included in the National
List will be conducted by them.
The drugs will be included in the
National List for International
Nonproprietary Names. National
List updates will be carried out
once a year.
Interested individuals and legal
entities can apply with a package
of necessary documents for
inclusion of drugs in the National
List of Medicines. To this end,
the development and public
discussion of the Regulation
on the conduct of medicines
selection for inclusion in the
National List, which will be
approved by order of the MOH,
as well as the application form
and its requirements is being
continued.
See all news on regulatory
updates on the Legal Alliance
website.
Parliament will consider healthcare
Draft Laws on Apr 12
Parliament will consider Draft
healthcare Laws on Apr 12
Ukrainian Parliament will hold
a thematic session to consider
Draft Laws in the sphere of
healthcare on Apr 12, the Speaker
Volodymyr Groysman said on Mar
28.
“I’m asking thw Apparatus of the
Parliament to process the list
of laws and positions on their
support for the next plenary
week,” Mr. Groysman said. “I would
also ask to connect associations
and learn the position of regional,
local councils on what should be
improved in healthcare.”
Previously, Parliamentary
Committee had approved the
Draft Law “On autonomation
of healthcare establishments”,
which is expected to start the
process of reformation of the
National healthcare system. The
Draft Laws on transplantation
and increase of wages to medical
workers are also to be considered
by deputies.
Parliamentary Committee rejected
the Draft Law to reduce drugs
prices
On Mar 30, during the meeting
of the Parliamentary Committee
of Public Health, the PMs
considered the Draft Law 1376
“On Amendments to the Tax
Code of Ukraine and some other
legislative acts of Ukraine (on
reducing prices on drugs).” The
document proposed to establish
extra charges for distributors and
retailers at the level of 3% and 5%,
respectively, for all medicines and
medical devices.
The Committee Members rejected
the Draft Law, stating that it is
contrary to current legislation.
Moreover, it could provoke the
extinction of many drugs on
the pharmaceutical market of
Ukraine. According to PM Irina
Sysoenko, the only way to solve
pricing issue is to implement
reimbursement mechanism.
HEALTHCARE NEWS
Ukraine’s PM: Minimal guarantee
level of free medical services to be
introduced this year
The government plans to
implement the guaranteed
level of free medical services in
2016 within healthcare system
reformation, the PM of Ukraine
Arseniy Yatsenyuk stated. “Free
health care services should
be provided through the State
Medical Insurance Fund, where
each Ukrainian citizen must be
insured,” Mr. Yatsenyuk said.
MOH and insulin producers signed
Memorandum of understanding
The MOH and the range of
insulin producers have signed the
Memorandum of Understanding
defining the order of joint
activities aimed at providing of
Ukrainians with insulin drugs as
well as successful implementation
of the pilot project on insulin
reimbursement.
The following companies have
signed the Memorandum: Farmak,
Indar, Sanofi-Aventis Ukraine LLC,
Bioton S.A., Eli Lilly Vostok S.A.,
Novo Nordisk A/T, Pharma Life
LLC. The pilot project is expected
to start acting since Apr 1, 2016.

The MOH is discussing
development of new drug policy
Among the MOH’s main tasks
is the provision of access to
drugs, containing narcotic and
psychotropic substances to
patients requiring them, the
Healthcare Minister Kvitashvili
said during the public discussion
on 03/03/2016. The issue
of decriminalization of drugs
consumers, which keep them in
small amounts without intent
to sell, is also essential, Mr.
Kvatashvili said.
Excessive over-regulation
of medical circulation of
preparations leads to significantly
limited access to pain relief for
patients with severe diseases,
mental illness and addiction, the
acting Head of State Drug Control
Service stressed.
All members of the discussion
concluded the Ukraine’s need to
reconsider approaches in state
drug policy towards humanization
and efficiency.
The Cabinet of Ministers
announced tasks in HC for 2016
The Ukrainian government
announced 379 tasks to be
done by the Cabinet of Ministers
together with the President and
the Parliament in 2016. The
following functions defined sphere
of healthcare:
»» “Money follows the patient” –
creation of a new system of
medical services financing.
Finance Ministry and Ministry
of Social Policy will need
to develop legislative acts
to implement the state-
guaranteed package of
health services. The task
also foresees the creation of
National Agency on healthcare
financing.
»» The new system of public
procurement of drugs – until
Aug 31 the MoH and Economic
Development Ministry must
develop legislative acts
regulating the centralized
procurement organization in
healthcare.
»» The new primary medical care
– developing a new model of
primary healthcare provision
»» Public health – protection
and strengthening of national
health.
»» The availability of high-
quality and efficient drugs
– adoption of National policy
on drugs following the WHO
recommendations.
Antituberculosis program for
2017-2021 is under development
Ukraine is developing the program
on fighting tuberculosis for
2017-2021, which considers
new approaches to the disease
treatment, the Director of
Ukrainian Center for controlling
socially dangerous diseases of the
MOH Natalia Nizova said. Ukraine
has 28 ths officially registered
persons with tuberculosis while
50% of tuberculosis hospitals
do not meet the requirements of
infection control.
Israeli experts are ready to share
experience on development of
efficient HC system with Ukraine
Israeli experts and physicians are
ready to share with Ukraine the
experience on the development
of efficient healthcare system,
but the reforms should be carried
by Ukrainian colleagues, Israel’s
ambassador to Ukraine Eliav
Belotserkovsky said.
Israeli partners intend to hold
lectures in establishments
of medical education in
Ukraine and start elaborating
with Parliamentary Public
Health Committee. Ukrainian
professionals also expect to
take over the practices of family
doctors and primary care.

Business
Consulting
HR-Consulting
Market
Access
Business
Education
Support of M&A Deals / Pre-investment Due Diligence
Commercial Audit / Business Diagnostics
FCPA Audit / Reputational Audit
Executive Search / Recuiting
Organizational Consulting / Personnel Assessment
Outplacement
Launch Planning / Marketing Analysis & Planning
Regulatory Environment Audit / Business Modelling
Analysis of Prescribers and Consumers
Business Training for Pharmaceutical Companies:
Strategy / Change Management
New Launches / Marketing
UPharma Consulting is
a consulting company,
operating in the healthcare
and pharma sectors. Our
clients - pharmaceutical
companies, pharmacy
chains, distributors,
investment funds, banks,
and other stakeholders.
UPharma Consulting
21st
Marshal Tymoshenko str.,
building 7, office 5
Kiev, 04212
Ukraine
+380 (44) 232 1142
+380 (44) 232 1143
www.upharma-c.com
mailbox@upharma-c.com
Subscribe to
Upharmacia
instantly!

Upharmacia - March 2016

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (7)

Similar to Upharmacia - March 2016

Similar to Upharmacia - March 2016 (15)

More from Eirhub

More from Eirhub (10)

Recently uploaded

Recently uploaded (20)

Upharmacia - March 2016